1. 2nd Annual Diabetes
and Diabetic Retinopathy
Identifying new therapeutic opportunities for diabetes and diabetic retinopathy
15th - 16th June 2011, Visiongain Conference Centre, London, UK BOOK NOW!
Key Speakers
Dr. Peter Adamson, Vice President and Head of Research Ophthiris, GlaxoSmithKline
Dr. Richard Carr, Senior Director, Merck Sharp & Dohme
Dr. Hans-Jürgen Wörle, Vice President, Therapeutic Area Head Metabolism,
Boehringer Ingelheim Pharma GmbH & Co. KG
Dr. Michael Mark, Vice president, Therapeutic Area CardioMetabolic Diseases Research,
Boehringer Ingelheim Pharma GmbH & Co. KG
Dr. David H Solomon, President , Chief Executive Officer, Zealand pharma A/S
Dr. Rob Jones, Senior Director, Medicinal Chemistry, Arena Pharmaceuticals
David M. Kendall, Chief Scientific and Medical Officer, American Diabetes Association
Dr. Araneo Barbara, Director of Complications Research, Juvenile Diabetes Research Foundation
Dr. Ennio Ongini, Vice President Research, NicOx
Dr. Selwyn Ho, Sr.Director, Marketing, Retina, Allergen EAME
Professor. P.M. Dodson, M.D, FRCP, FRCOphth Consultant, Diabetes & Medical Ophthalmology,
Birmingham Heartlands Hospital, Birmingham, UK
Professor Sue Lightman, Professor of Clinical Ophthalmology and Consultant Ophthalmologist, Institute of
Ophthalmology, University College London / Institute of Ophthalmology and Moorfields Eye Hospital
Alireza Falahati-Nini, M.D, FACE President, Utah Endocrinology Associates Medical Director,
St. Mark’s Hospital Diabetes Center
Simon Taylor MA PhD FRCOphth, NIHR Clinical Lecturer in Ophthalmology, UCL Institute of Ophthalmology
Driving the Industry Forward | www.futurepharmaus.com
Media Partners Organised By
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/diabetes

2. Conference Introduction
2nd Annual Diabetes and Diabetic Retinopathy
15th - 16th June 2011, London, UK
Dear Colleague, Media Partners:
iabetes is becoming an epidemic and is expected to reach $86.9 billion by 20251;
D PharmiWeb.com is the leading industry-sponsored portal for
world health organisation predicts that 4.4% of the world population will have the pharmaceutical sector. Supported by most of the leading
diabetes by 2030. Of the 246 million people with diabetes about third have signs pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news,
of diabetic retinopathy3 and about third of these might have vision –threatening features, events listings and international jobs to industry professionals across Europe
retinopathy defined as severe retinopathy or macular oedema4. and the US.
esearch is constantly going on to develop a better understanding of physiologic
R For further information please email: corporate@pharmiweb.com
characteristics of type 1 and type 2. Recognition of the contribution of fasting and
postprandial blood glucose levels to overall glycemia, new treatment approaches
that focus on achieving tight glycemic control and other therapeutic options that BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY
allow the practitioner to develop treatments tailored to meet the individual patient WORLD. It is based and located in Warsaw, Poland.
needs are being addressed. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma
isiongain’s 2nd Annual Diabetes and Diabetic Retinopathy conference is designed to
V information and market to make it universally accessible and useful for scientific
bring together the industry experts to discuss every aspect of drug development for and business processes. Its first step to fulfilling that mission was building the
diabetes, from latest clinical development through to dealing with regulatory issues. BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in
different channels. BIOTECHNOLOGY EUROPE offers companies completed internet
By attending this conference, you will: public relations, publication and marketing solutions. One of the mains goals of
• ssess new developments in currently used treatments –Human insulins and
A BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to
analogues,DPP-IV inhibitors, Sulphonylurea and Biguanide, Alpha-Glucosidase global biotechnology, pharmaceutical and life science activities.
Inhibitor, GLP-1 agonist, SGLT inhibitor etc For further information please visit: www.biotechnology-europe.com
• ain insight about the future market trends in insulin, oral anti-diabetic and non
G
insulin injections
Future Pharmaceuticals has forged powerful relationships
Driving the Industry Forward | www.futurepharmaus.com
• ind new treatments for diabetes
F
with key industry leaders to provide a platform for successful
• vercome challenges in developing novel anti-diabetic therapies
O
brand recognition, and for senior decision-makers to have the means to procure and
• valuate the latest clinical development for diabetic retinopathy
E plan implementation strategies based on the topics covered. Positioned to be an
• ffectively target glycaemia and blood pressure levels for prevention of
E authoritative resource within top pharma companies as well as small, specialty, and
retinopathy development and progression biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into
• dvance role of lipid lowering therapy
A a highly targeted and responsive audience, bridging the gap between the industries’
• nderstand the new medical treatments in diabetic retinopathy –ocular therapy
U top issues and the solutions top-tier vendors can provide.
For further information please visit: www.futurepharmaus.com
(laser photocoagulation)
• xplore emerging ophthalmic treatments –Glucocorticoids and the role of drug
E
delivery systems in the management of Diabetic Macular Edema and Anti-VEGF
therapy InPharm is the online platform for exclusive pharmaceutical
news, comment, contracts, services, jobs and events and is
• xamine the challenges in regulating development & approval of drugs in
E home to InPharmjobs.com, Pharmafile and Pharmafocus.
Diabetes For further information please visit: www.In-Pharm.com
I look forward to meeting you at the conference
Best regards
Glycosmedia is a free, non-promotional, editorially independent
diabetes news service for healthcare professionals. Its function
is to bring the latest diabetes news and information to those
working in the field of diabetes, both in the clinic and in research. A free weekly e-mail
newsletter is also available.
Sonia Tomar For further information please visit: http://www.glycosmedia.com/
Conference Producer
Who will be there? Sponsorship and exhibition opportunities
Presidents, Chief Executives, Chief Scientific Officers, Chief
Operating Officers, Senior Vice Presidents, Vice Presidents, Heads, This event offers a unique opportunity to meet and do business with some
Senior Directors, Directors, Clinicians, Principal Scientists, Principal of the key players in the pharmaceutical and biotech industries. If you have
Investigators, Managers, Project/Team Leaders in:
a service or product to promote, you can do so at this event by:
• Diabetes & Obesity, Pre-Clinical and Clinical R&D
• Retinal Diseases • Hosting a networking drinks reception
• Ophthalmology, Visual Science and Vision Research • Taking an exhibition space at the conference
• Endocrinology and Metabolic Diseases • Advertising in the delegate documentation pack
• Cardiovascular and Gastrointestinal Diseases
• Anti-Diabetic Agents & Advanced Diabetes Systems • Providing branded bags, pens, gifts, etc.
• Drug Development If you would like more information on the range of sponsorship or
• Monoclonal Antibodies
• Molecular Neuroscience
exhibition possibilities for visiongain's 2md Annual Diabetes and Diabetic
• New Products Global Marketing Retinopathy Conference, please contact us:
• Business Development, Licensing & Partnership
• Venture Capital Ronald Magali, +44 (0)20 7549 9934
• Regulatory Affairs ronald.magali@visiongainglobal.com
1
Visiongain, (2010). World Diabetes Market Analysis Report, 2010-2025.
2
International Diabetes Federation .Diabetes atlas 2007.http://www.eatlas.idf.org
3
Saaddine JB,Honeycutt AA,Narayan KM ,Zhang X,Klein R, Boyle JP .Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus:United States 2005-2050.Arch Opthalmol 2008;126:1740-47

3. Day 1
2nd Annual Diabetes and Diabetic Retinopathy
Wednesday 15th June 2011
09:00 Registration and refreshments 13:40 GPR119 Agonists for the treatment of Type 2 Diabetes
• Overview of GPR119
09:30 Opening address from the chair • Mechanism of glycemic control
• Clinical status
09:40 Perspective on emerging treatments for diabetic Dr. Rob Jones
retinal disease and the challenges for prevention Senior Director, Medicinal Chemistry
and treatment Arena Pharmaceuticals
• Overview on diabetes
• JDRF view of clinical unmet need 14:20 DPP-4 Inhibitors updates
- Reach out to adolescents and adults Dr. Richard Carr
- Screening and prevention Senior Director
- Sight-sparing treatment Merck Sharp & Dohme
• JDRF view of gaps in research
- Collaboration 15:00 Afternoon Refreshments
- Diagnostics
- Therapies 15:20 Treatment targets in diabetes: where do we stand
- Policy and reimbursement following ACCORD?
- Education • eview the history of studies in intensive glycemic control (from UGDP to
R
ACCORD) and discuss the impact of these interventions on microvascular
Dr. Barbara A. Araneo
complications in diabetes
Scientific Program Director - Complications Therapies
Juvenile Diabetes Research Foundation • iscuss the relative impact of early vs late intervention and its impact on
D
microvascular complications risk
• utline the findings of more recently published studies of more intensive
O
10:20 Finding new treatments for diabetes
glycemic control (ACCORD, ADVANCE and VADT) as relates to retinal
• DPP4- inhibitors
complications of diabetes
• SGLT-2 inhibitors
• eview the risk-benefit of more intensive treatment strategies as relates
R
Dr. Michael Mark to diabetes intervention
Vice president, Therapeutic Area Cardio Metabolic Disease •D
iscuss current treatment targets for glucose, lipids and blood pressure
Boehringer Ingelheim Pharma GmbH & Co. KG following completion of the ACCORD trial
David M. Kendall, MD
11:00 Morning refreshments Chief Scientific and Medical Officer
American Diabetes Association
11:20 Examine the challenges in regulating development
& approval of drugs in diabetes 16:00 Review of current and emerging - DPP-4 Inhibitors
• mplication of the new FDA CV guidance, can one still develop
I and GLP-1 Analogs
gluco-centric compounds? • eview of the Physiology of Incretins (GLP-1 and GIP) as well as
R
• hat is feasible size of a phase III program in the light of the
W DPP-4 Inhibitors
new requirements? • eview of current and emerging drugs from the GLP-1 and DPP-4
R
• What patients should be included and at what stage of the CDP? Inhibitor classes
Dr. Hans-Jürgen Wörle • eview of current evidence for “Beta-Cell Preservation” in animals
R
Vice President, Therapeutic Area Head Metabolism (and Humans?)
C MED Clinical Development & Medical Affairs • eview of current evidence of positive effect of these two classes on
R
Boehringer Ingelheim Pharma GmbH & Co. KG cardiovascular health
• eview of long-term data (5-year +) on sustainability of diabetes
R
12:00 GLP-1 - new treatment paradigms in diabetes - The management with these two new classes
Zealand Pharma Story • Potential Adverse effects and why?
• Overview of GLP-1s Alireza Falahati-Nini, M.D., FACE
• he discovery at Zealand of Lixisenatide and its commercialisation by
T President, Utah Endocrinology Associates
sanofi-aventis Medical Director, St. Mark’s Hospital Diabetes Center
• New directions of GLP-1s in the treatment of diabetes and related obesity
Dr. David H Solomon 16:40 Closing remarks from the chair
President, Chief Executive Officer
ZEALAND Pharma A/S
16:50 Networking drinks
12:40 Networking lunch Take your discussions further and build new
relationships in a relaxed and informal setting
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011

4. Day 2
2nd Annual Diabetes and Diabetic Retinopathy
Thursday 16th June 2011
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the chair
Professor Sue Lightman 13:40 Emerging ophthalmic treatments
Professor of Clinical Ophthalmology -Anti-VEGF therapy
UCL/Institute of Ophthalmology and
• Rationale for anti-VEGF agents in diabetic macular edema
Moorfields Eye Hospital
• Types of anti-VEGF agents in use
09:40 Role of lipid lowering therapy in diabetes retinopathy • Results of the main clinical studies./ trials
 • ow do lipids influence eye disease?
H
 • elationship of lipids and diabetic retinopathy
R • Comparison with other treatment modalities
 • otential mechanisms of retinal damage by lipids
P • Their use in clinical practise
 • reatment of retinopathy with lipid lowering drugs:
T
statins and fibrates Professor Sue Lightman
• ARDS, FIELD, ACCORD-EYE Studies
C Professor of Clinical Ophthalmology
• onclusion
C UCL/Institute of Ophthalmology and
Moorfields Eye Hospital
PROFESSOR. P.M. DODSON, MD, FRCP, FRCOphth
Consultant, Diabetes & Medical Ophthalmology, Departments of Diabetes,
Ophthalmology, & Heart of England Diabetic Retinopathy Screening Centre
Birmingham Heartlands Hospital, Birmingham, UK 14:20 Emerging medical treatments - Ocular therapy
• Advances in laser for proliferative disease
10:20 Nitric oxide-donating glucocorticoids for effective
• Advances in laser for diabetic macular oedema
and safe treatment of diabetic macular edema
• argeting nitric oxide (NO) for the treatment of eye diseases
T • Where are we now? - results of the clinical trials
• itric oxide and IOP lowering
N
• Role of vitreoretinal surgery
• itric oxide and oxygen saturation of the retina and ONH
N
• otential of NO-donating glucocorticoids
P Simon Taylor MA PhD FRCOphth
Dr. Ennio Ongini NIHR Clinical Lecturer in Ophthalmology
Vice President Research UCL Institute of Ophthalmology
NicOx
11:00 Morning refreshments 15:00 Afternoon refreshments
11:20 Pazopanib eye drops in mouse models of diabetic
eye disease 15:20 Systemic therapy in treatment of diabetic retinopathy
• Pazopanib is a multi-spectral tryrosine kinase inhibitor • arget glycaemia and blood pressure levels of effective prevention of
T
• Pazopanib eye drops are in PhIIb development for neovascular AMD retinopathy development and progression
• ill discuss efficacy of pazopanib in models of vascular leak and
W
retinal neovascularisation • fficiency of hypoglycaemic and blood pressure lowering agents
E
Dr. Peter Adamson
Vice President and Head of Research Ophthiris
GlaxoSmithKline 16:00 Pharmacological inhibition of diabetic retinopathy
• ldose reductase inhibitors
A
12:00 Emerging ophthalmic therapies: Glucocorticoids and
• nti-inflammatory methods
A
the role of drug delivery systems in the management
of diabetic macular edema • rotein kinase C activation and its pharmacological inhibition in
P
• he pathophysiology of diabetic macular edema (DME) has a clear
T vascular disease
inflammatory component
• lucocorticoids have been a key part of the armamentarium for the
G
management of DME, both in monotherapy and in combination with 16:40 Chair’s closing remarks
other modalities
• ifferences in the glucocorticoid molecular structure, routes of administration
D
and pharmacokinetic profiles may result in clinically relevant differences
• n a long-term, chronic disease such as DME, Glucocorticoids in long
I 16:50 End of conference
duration drug delivery systems may play a role in reducing the burden of
drug administration to patients, physicians and health care systems
Dr. Selwyn Ho
Sr. Director, Marketing, Retina
Allergen EAME

5. Registration Form
2nd Annual Diabetes and Diabetic Retinopathy
15th - 16th June 2011, London, UK
Angel
Conf. code VG Pentonville Road
2nd Annual Diabetes and
Ci
Standard Prices
ty
Diabetic Retinopathy
Ro
ad
Conference only Fee: £1299 VAT: £259.80 Total: £1558.80
15th - 16th June 2011
Old Street
Number of bookings: Total cost: Location: Visiongain Conference Centre Old Street
Address:
230 City Road
Promotional Literature Distribution
City Road
London
Distribution of your company’s promotional literature to all conference attendees EC1V 2TT
UK
Fee: £999 VAT: £199.80 Total: £1198.80
Details How to book
Forename: Surname: Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/diabetes
Job Title: Company: UK Office:
Tel: +44(0) 20 7336 6100
Fax: +44(0) 20 7549 9932
Main Switchboard Number:
Visiongain Ltd
BSG House
Address: 226-236 City Road
London
EC1V 2QY
UK
Country: Postcode: General information
Venue: Venue: Directions: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United
Phone: Fax: Kingdom. Closest tube station is Old Street (Northern Line).
Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376
9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343
Email: http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html
Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207
Signature: 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
I confirm that I have read and agree to the terms and conditions of booking Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
right to charge interest on unpaid invoices.
Methods of payment
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
Payment must be made in sterling made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
after one month before the start of the event. Should you decide to cancel after this date, the full invoice
By Mail: Complete and return your signed registration form together with your cheque payable must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK between conferences. However, if you cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email, fax or post. Name changes and
By Fax: Complete and fax your signed registration form with your credit card details substitutions must be from the same company or organisation and are not transferable between
countries. Please note that discounted delegates places at a visiongain event are non refundable.
to +44 (0) 20 7549 9932
Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932
Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
By Bank Transfer: briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
Visiongain Ltd A/C: visiongain Ltd to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
expenses, which may be incurred by the customer as a consequence of the event being postponed or
Barclays Bank Sort Code: 20-71-64
cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
Piccadilly Branch Account No: 6038 7118 cost of the registration, travel and expenses.
48 Regent Street Swift Code: BARC GB22
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
London, W1B 5RA IBAN: GB80 BARC 20716460387118 Protection Act 1988. Your personal information contained in this form may be used to update you on
visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
Please debit my credit card: may also share your data with external companies offering complementary products or services. If you
wish for your details to be amended, suppressed or not passed on to any external third party, please
Access MasterCard Visa American Express send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
Card number: visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
Expiry Date: recommend you obtain).
VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
Security number (last 3 digits on back of credit card): incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Signature: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Cardholder’s name: Unable to attend
Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
News updates with your payment. You will receive speaker talks in PDFs two weeks after the event.
Please tick if you do not want to receive email news updates in the future Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
www.visiongain.com/diabetes